In the British pharmaceutical industry, there were 11 private equity deals announced in Q3 2023, worth a total value of $951.1m, according to GlobalData’s Deals Database. The $884.8m acquisition of Ergomed by Permira Advisers in a going private transaction was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.

In value terms, private equity deal activity in the UK remained flat in Q3 2023 compared with the previous quarter and as compared to Q3 2022. Related deal volume increased by 120% in Q3 2023 versus the previous quarter and was 120% higher than in Q3 2022.

The top-ranked financial advisors supporting these private equity deals in the UK in Q3 2023 were Jefferies Financial Group; Consilium Strategic Communications; Deloitte NSE with 2, 1, 1 deals respectively.

The top-ranked legal advisorss supporting these private equity deals in the UK Q3 2023 were Hill Dickinson; Macfarlanes; Covington & Burling with 2, 2, 1 deals respectively.

For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Buyouts and Direct Investments done by Private Equity firms.